SBC2

SBC2 is a synthetic chalcone-based small molecule compound investigated for its potential as an anticancer therapeutic. It has demonstrated the ability to suppress xenograft tumor growth in preclinical models of lung and bladder cancer. The mechanism of action involves the induction of cancer cell cytotoxicity through a novel pathway of autophagy-associated necroptosis. Specifically, SBC2 activates the JNK and ERK signaling pathways via their upstream kinases MEKK1 and MKK7. This activation leads to the phosphorylation of BCL-XL and the induction of autophagy, which ultimately triggers necroptotic cell death involving RIP1 and RIP3. The compound was developed through collaboration between the Lovelace Respiratory Research Institute, the University of Minnesota, and Chongqing Medical University.